Company intelligence / Profile preview

Clearbridge Biomedics

Ownership: Private
Development stage: Other

Overview

Clearbridge Biomedics has developed the proprietary ClearCell® FX System for label-free enrichment and isolation of circulating tumor cells from blood. The platform is deployed in research settings globally to advance liquid biopsy-based cancer diagnostics. The company participates in international consortia such as CANCER-ID to standardize blood-based biomarker protocols for oncology. Clinical results focus on enabling early detection and monitoring of cancers through non-invasive means; commercial diagnostic adoption is ongoing.

Therapeutic areas: OncologyCardiovascularEndocrinologyNeurology
Modalities: DeviceIn vitro diagnosticsGenetic testingLiquid biopsy technology
Industry: Molecular Diagnostics

Partnerships

LIDE BiotechCANCER-ID Consortium

Beyond the preview

Go deeper on Clearbridge Biomedics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clearbridge Biomedics.

Explore the full profile